These antibodies have been shown to cross-react with all erythropoietic proteins, and patients suspected or confirmed to have ng neutralising antibodies to erythropoietin should not be switched to darbepoetin alfa (see section 4.8). lo Active liver disease was an exclusion criteria in all studies of Nespo, therefore no data are available from patients with impaired liver function.
Az aktív májbetegség kizáró kritérium volt minden Nespo- vizsgálat során, ezért nem áll rendelkezésre adat károsult májfunkciós betegek esetén.